A peer-reviewed report points to the success of initial trials on humans test subjects in Wuhan of a Novel Coronavirus vaccine.
On 16 March the first stage of clinical trials of a COVID-19 recombinant vaccine commenced in the Hubei-province capital of Wuhan where the disease first emerged.
The vaccine was developed by a team led by epidemiologist Chen Wei (陈薇) from the Academy of Military Medical Sciences, with the involvement of Hong Kong-listed CanSino Bio-B.
A peer-reviewed report published by The Lancet now points to the initial success of the trial.
“This first-in-human trial showed that the Ad5 vectored COVID-19 vaccine was tolerable and immunogenic in healthy adults,” said the report.
“Humoral responses against SARS-CoV-2 peaked at day 28 post-vaccination in healthy adults, and rapid specific T-cell responses were noted from day 14 post-vaccination.
“One dose of the vaccine at all dose concentrations (5 × 1010, 1 × 1011, and 1·5 × 1011 viral particles) tested induced both specific antibody and T-cell responses in most participants. Rapid specific T-cell responses were noted at day 14 and specific humoral responses against severe acute respiratory syndrome coronavirus 2 peaked at day 28 post-vaccination. “
The trial involves a total of 108 trial participants, with a research and observation period of at least six months.
China recently completed work on the world’s largest vaccine plant with an annual capacity of 100 million doses. The plant will be dedicated to the production of COVID-19 vaccines.